TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1738926

Group type: EXPERIMENTAL
Intervention: ALG (Merieux) until serum creatinine was less than 300 mumol/L
Number of subjects: 110

Group type: COMPARATOR
Intervention: No rejection
Number of subjects: 110

Group type: COMPARATOR
Intervention: Steroid-sensitive rejection
Number of subjects: 110

Group type: COMPARATOR
Intervention: Steroid-resistant rejection
Number of subjects: 110

Group type: COMPARATOR
Intervention: First rejection
Number of subjects: 110

Group type: COMPARATOR
Intervention: Second rejection
Number of subjects: 110

Group type: COMPARATOR
Intervention: Third rejection
Number of subjects: 110

Group type: COMPARATOR
Intervention: Patients free of rejection
Number of subjects: 110

Group type: COMPARATOR
Intervention: Patients with delayed graft function and sensitized patients
Number of subjects: 110

Group type: COMPARATOR
Intervention: Patients with at least 1 rejection in the first 90 days
Number of subjects: 110

Group type: COMPARATOR
Intervention: Patients with stable renal function
Number of subjects: 110

Group type: COMPARATOR
Intervention: 1 year SCr for patients without rejection
Number of subjects: 110

Group type: COMPARATOR
Intervention: 1 year SCr for patients with steroid-sensitive rejection
Number of subjects: 110

Group type: COMPARATOR
Intervention: 1 year SCr for patients with steroid-resistant rejection
Number of subjects: 110
Study: 6325522

Group type: EXPERIMENTAL
Intervention: Vasodilators (isosorbide dinitrate, minoxidil, enalapril or captopril)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 30502047

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg daily plus P2Y12 inhibitor monotherapy (Group 1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT) (Group 2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard-of-care vitamin K antagonist and DAPT (Group 3)
Number of subjects: 3
Study: 28447159

Group type: EXPERIMENTAL
Intervention: Short-term adjunctive antiarrhythmic drug therapy with amiodarone (group A) for the first 3 months
Number of subjects: 230

Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy except for beta blockers (group B)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Short-term adjunctive antiarrhythmic drug therapy with amiodarone (group A)
Number of subjects: 230
Study: 27515716

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 2267

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) levels
Number of subjects: 2267

Group type: COMPARATOR
Intervention: HbA1c of 5.7-6.4% (39-46mmol/mol)
Number of subjects: 2267

Group type: COMPARATOR
Intervention: FPG of 5.5-6.9mmol/L
Number of subjects: 2267
Study: 25060541

Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (FF) 9.6 μg MDI
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (FF) 2.4 μg MDI
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (FF) 4.8 μg MDI
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Foradil (FA) 12 μg
Number of subjects: 34
Study: 23209840

Group type: EXPERIMENTAL
Intervention: Alcohol treatment (BACs of 0.048%)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Alcohol treatment (BACs of 0.082%)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Alcohol treatment (BACs of 0.10%)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Alcohol treatment (BACs of 0.00%)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Inspection Time (IT) test
Number of subjects: 56
Study: 20833874

Group type: EXPERIMENTAL
Intervention: Surgical treatment (suture repair of the injured ligament(s) within the first week after injury, followed by a below‐the‐knee plaster cast for six weeks with full weight‐bearing)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Functional treatment (use of an Aircast ankle brace for three weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Functional treatment
Number of subjects: 51
Study: 18768021

Group type: EXPERIMENTAL
Intervention: New manual toothbrush with modified shape
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditionally shaped toothbrush
Number of subjects: 16
Study: 16416642

Group type: EXPERIMENTAL
Intervention: Restylane 0.7 mL
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hylaform 1.0 mL
Number of subjects: 8
Study: 12826972

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (33.0 to 34.0 degrees C) combined with barbiturate coma
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mild hypothermia for <72 hours (group 1: mean 42.2 hours)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mild hypothermia for >72 hours (group 2: mean 153.9 hours)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mild hypothermia and barbiturate coma
Number of subjects: 21
Study: 10530413

Group type: EXPERIMENTAL
Intervention: Thrombocytopenic HIV‐1 infected patients
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Non-thrombocytopenic HIV‐1 infected patients
Number of subjects: 88

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Autoimmune thrombocytopenic purpura (AITP) group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mild thrombocytopenic group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pancytopenic patients
Number of subjects: 88
Study: 8770739

Group type: EXPERIMENTAL
Intervention: Peri-operative guanethidine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 71
Study: 2239757

Group type: EXPERIMENTAL
Intervention: Formula with 40% medium-chain triglycerides and added L-carnitine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Formula with 40% medium-chain triglycerides without added L-carnitine
Number of subjects: 20
Study: 110520

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 243

Group type: COMPARATOR
Intervention: Penicillin-V
Number of subjects: 243
Study: 31037378

Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 40
Study: 31444180

Group type: EXPERIMENTAL
Intervention: MRI-based active surveillance protocol with standardised triggers for repeated biopsies and radical treatment
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Current practice surveillance
Number of subjects: 2000
Study: 28650566

Group type: EXPERIMENTAL
Intervention: Immediate insertion of LNG-IUS (n=134)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Delayed insertion of LNG-IUS (n=133)
Number of subjects: 267
Study: 27509703

Group type: EXPERIMENTAL
Intervention: Drug treatment and aspiration of abscess cavity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug treatment alone
Number of subjects: 0
Study: 24090370

Group type: EXPERIMENTAL
Intervention: Community mobilization focusing on birth planning and hospital transport, community birth attendant training in problem recognition, and facility staff training in the management of obstetric and neonatal emergencies.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 0
Study: 21943067

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification advice (3-monthly)
Number of subjects: 4600

Group type: COMPARATOR
Intervention: Less-intensive lifestyle modification advice (12-monthly; control group)
Number of subjects: 4600
Study: 18280963

Group type: EXPERIMENTAL
Intervention: Separate consultation with an oral and maxillofacial surgeon before surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard information provided just before surgery
Number of subjects: 0
Study: 17161066

Group type: EXPERIMENTAL
Intervention: Invasive treatment (PCI)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 365
Study: 12749435

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (12.5 mg/d for the first 10 days of the cycle)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/d)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg/d)
Number of subjects: 41
Study: 10886477

Group type: EXPERIMENTAL
Intervention: Smoker stickers intervention
Number of subjects: 393

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 393
Study: 1331443

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg once daily for four weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily for four weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg once daily for six weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 100
Study: 3904570

Group type: EXPERIMENTAL
Intervention: diclofenac sodium 50 mg tid
Number of subjects: 100

Group type: COMPARATOR
Intervention: matching placebo tid
Number of subjects: 100
Study: 30476587

Group type: EXPERIMENTAL
Intervention: Fluticasone (n=16)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Regression-based overall score (n=16)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Not applicable (placebo group, n=8)
Number of subjects: 266
Study: 30078660

Group type: EXPERIMENTAL
Intervention: 8 mg intravenous dexamethasone
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 25762016

Group type: COMPARATOR
Intervention: Standard polyethylene (SP) tibial inserts
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: XLP polyethylene liner
Number of subjects: 192
Study: 22677231

Group type: EXPERIMENTAL
Intervention: Online self-help program for depression (Deprexis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 0
Study: 20154055

Group type: EXPERIMENTAL
Intervention: MAPS/MAPS+
Number of subjects: 251

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 251
Study: 18664303

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15964709

Group type: EXPERIMENTAL
Intervention: Cranial radiotherapy (RT) at 50.4 Gy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cranial radiotherapy (RT) at 64.8 Gy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cranial radiotherapy (RT)
Number of subjects: 20
Study: 12118026

Group type: EXPERIMENTAL
Intervention: Irinotecan (350 mg/m² intravenously for 90 minutes) alone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Irinotecan (100 mg/m²) with ketoconazole (200 mg orally for 2 days)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Irinotecan (350 mg/m²) alone
Number of subjects: 7
Study: 10203560

Group type: EXPERIMENTAL
Intervention: Dietary lycopene intake
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Plasma cholesterol
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Study site
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Income level
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Race/ethnicity
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Vitamin C consumption
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Stepwise regression analysis
Number of subjects: 111
Study: 8710065

Group type: EXPERIMENTAL
Intervention: rIFNA (9 million IU intramuscular every other day for 6 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1495453

Group type: EXPERIMENTAL
Intervention: Desmopressin (oral administration)
Number of subjects: 12
Study: 6365448

Group type: EXPERIMENTAL
Intervention: Delta Lippes Loop
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Delta TCu22OC
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: TCu22OC (non-sutured)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: TCu22OC (sutured)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: All IUD models
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Delta Loop
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: TCu22OC
Number of subjects: 906
Study: 31961419

Group type: EXPERIMENTAL
Intervention: Early surgery (pancreatic drainage surgery within 6 weeks after randomization)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 88

Group type: COMPARATOR
Intervention: Endoscopy-first approach
Number of subjects: 88
Study: 30277850

Group type: EXPERIMENTAL
Intervention: Three-month anti-inflammatory diet
Number of subjects: 20
Study: 30138230

Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT) with modified Rankin Scale (mRS) as anchor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT) with Stroke Impact Scale (SIS) as anchor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT) for IGS <0.40 m/s with modified Rankin Scale (mRS) as anchor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT) for IGS <0.40 m/s with Stroke Impact Scale (SIS) as anchor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT) for IGS ≥0.40 m/s with modified Rankin Scale (mRS) as anchor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT) for IGS ≥0.40 m/s with Stroke Impact Scale (SIS) as anchor
Number of subjects: 0
Study: 26511764

Group type: EXPERIMENTAL
Intervention: Worry postponement intervention (30-minute period in the early evening)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Registration group (no intervention)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Worry postponement intervention
Number of subjects: 361
Study: 23995813

Group type: EXPERIMENTAL
Intervention: Special physiotherapeutic training
Number of subjects: 46
Study: 22954905

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 114

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 114
Study: 20571455

Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 138

Group type: COMPARATOR
Intervention: Without tourniquet
Number of subjects: 138
Study: 17327245

Group type: EXPERIMENTAL
Intervention: Albendazole (during pregnancy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel (during pregnancy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole (three-monthly from age 15 months to 5 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (during pregnancy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (three-monthly from age 15 months to 5 years)
Number of subjects: 0
Study: 15713723

Group type: EXPERIMENTAL
Intervention: Testosterone (Te)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Recombinant human IGF‐I
Number of subjects: 16
Study: 11907491

Group type: EXPERIMENTAL
Intervention: 12.5 mg almotriptan
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 25 mg almotriptan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10446889

Group type: EXPERIMENTAL
Intervention: Trauma patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 23
Study: 7789897

Group type: EXPERIMENTAL
Intervention: VitaCuff catheter
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard triple lumen catheters (control)
Number of subjects: 133
Study: 1915205

Group type: EXPERIMENTAL
Intervention: Linoleate-rich diet (23% energy from polyunsaturated fatty acids)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Linoleate-rich diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saturated fatty acid-rich diet (30% energy)
Number of subjects: 12
Study: 6958474

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA) 100 micrograms q.i.d.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Budesonide aerosol 10 micrograms q.i.d.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Budesonide aerosol 50 micrograms q.i.d. with Inhalet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31871115

Group type: EXPERIMENTAL
Intervention: Atezolizumab (one dose prior to cisplatin CRT, followed by two doses during CRT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atezolizumab (three doses during CRT)
Number of subjects: 40
Study: 30134301

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg, orally) administered the night before surgery and 2 hours before anesthesia induction
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg, orally)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo (vitamin B)
Number of subjects: 122
Study: 28490565

Group type: EXPERIMENTAL
Intervention: ipragliflozin (50 mg daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: metformin (1000 mg daily)
Number of subjects: 106
Study: 26062822

Group type: EXPERIMENTAL
Intervention: Iterative Bayesian PK-guided dosing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard dosing procedure
Number of subjects: 60
Study: 24645687

Group type: EXPERIMENTAL
Intervention: double unrelated umbilical cord blood (dUCB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HLA-haploidentical related donor bone marrow (haplo-BM)
Number of subjects: 0
Study: 22811033

Group type: EXPERIMENTAL
Intervention: Task-specific training protocol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 52
Study: 19770395

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 23665

Group type: EXPERIMENTAL
Intervention: Combination of telmisartan and ramipril
Number of subjects: 23665

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 23665
Study: 17195950

Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-ADHD controls
Number of subjects: 61
Study: 14698825

Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 100
Study: 12408447

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus and bulgaricus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG, Bifidobacterium longum, Enterococcus faecium SF68
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics in general
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacterial recovery assessment in stools
Number of subjects: 0
Study: 9566654

Group type: EXPERIMENTAL
Intervention: Movement and swimming program (swimming sessions twice weekly and group physical activity once weekly, each lasting 30 minutes for 6 months)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bobath physical therapy (30 minutes, 4 days per week)
Number of subjects: 46
Study: 8594692

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 102

Group type: COMPARATOR
Intervention: Quinine infusion
Number of subjects: 102
Study: 2496707

Group type: EXPERIMENTAL
Intervention: Skills training intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture on 'safer sex' without skills training
Number of subjects: 0
Study: 484357

Group type: EXPERIMENTAL
Intervention: Glycerol test with expectation of hearing improvement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycerol test with expectation of hearing deterioration
Number of subjects: 0
Study: 30640726

Group type: EXPERIMENTAL
Intervention: Cognitive-motor group (physiotherapy plus cognitive training)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Motor group (motor physiotherapy)
Number of subjects: 58
Study: 28266779

Group type: COMPARATOR
Intervention: semaglutide
Number of subjects: 30
Study: 25955225

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg) and calcitriol adjusted to achieve iPTH < 300 pg/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients not receiving denosumab)
Number of subjects: 0
Study: 24074668

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic endorectal pull-through (SILEP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional laparoscopic endorectal pull-through (CLEP)
Number of subjects: 58
Study: 23070071

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP), 20 mg/m × 5 days every 21 days (arm A)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Cisplatin (CDDP), 40 mg/m per week (arm B)
Number of subjects: 326
Study: 19402938

Group type: EXPERIMENTAL
Intervention: Quercetin 150 mg/d
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 17705756

Group type: COMPARATOR
Intervention: Commercially available balloon expander (Group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Original dissecting balloon (Group 2)
Number of subjects: 20
Study: 15165532

Group type: EXPERIMENTAL
Intervention: Chinstrap
Number of subjects: 15
Study: 11499188

Group type: EXPERIMENTAL
Intervention: Video (45-minute duration)
Number of subjects: 176

Group type: COMPARATOR
Intervention: CD-ROM (interactive)
Number of subjects: 176
Study: 9683400

Group type: EXPERIMENTAL
Intervention: PUFA-diet (34 E% fat, 10 E% polyunsaturated fat)
Number of subjects: 29

Group type: COMPARATOR
Intervention: MUFA-diet (40 E% fat, 19 E% monounsaturated fatty acids)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both diet groups
Number of subjects: 29

Group type: COMPARATOR
Intervention: PUFA-diet vs MUFA-diet
Number of subjects: 29
Study: 7850818

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 40
Study: 2974769

Group type: EXPERIMENTAL
Intervention: Domperidone (DA2-antagonist) with ANP infusion
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Domperidone (DA2-antagonist) with head-down tilt
Number of subjects: 14

Group type: COMPARATOR
Intervention: ANP infusion
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Head-down tilt
Number of subjects: 14